SCHEMBL5785346

SCHEMBL5785346

COc1cc(CC(C)(C)NC(=O)c2ccc(Cl)nc2)cc2c1OC(C)(C)C2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.39
CTNNB1 P35222 1/20 0.36
TCF7L2 Q9NQB0 1/20 0.36
GAA P10253 1/20 0.36
KCNQ3 O43525 1/20 0.36
KCNQ2 O43526 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MITF O75030 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5784882 0.76 KMT2A (0.32) KMT2A
SCHEMBL5785150 0.75 IDO1 (0.41) KMT2ANPC1LMNAKDM4EMAPT
SCHEMBL5784632 0.74 KMT2A (0.36) KMT2AMEN1GAANPC1LMNA
SCHEMBL5782999 0.72 KMT2A (0.41) KMT2ANPC1LMNAALDH1A1
SCHEMBL5785355 0.71 MEN1 (0.38) KMT2AMEN1GAANPC1LMNA
SCHEMBL5783751 0.71 HTR2A (0.40) KMT2ANPC1LMNAKDM4EALDH1A1
SCHEMBL5786313 0.69 NPC1 (0.39) KMT2AGAANPC1LMNAKDM4E
SCHEMBL5782881 0.67 NPC1 (0.53) GAANPC1LMNAALDH1A1MAPT
SCHEMBL2090351 0.67 GAA (0.52) KMT2AMEN1GAANPC1LMNA
SCHEMBL5786290 0.67 KMT2A (0.42) KMT2ANPC1LMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1270577-B1 FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-12-06 EP disclosed
US-6924292-B2 Furoisoquinoline derivatives, process for producing the same and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-02 US disclosed
US-20040092582-A1 Furoisoquinoline derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 US disclosed
EP-1270577-A1 FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092582-A1 Furoisoquinoline derivatives, process for producing the same and use thereof PDE3B, PDE5A, PDE3A KMT2A 1140/4885MEN1 2243/4885CTNNB1 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.